1. Effect of bromhexine on clinical outcomes and mortality in COVID-19 patients: A randomized clinical trial

Khalil Ansarin , Ramin Tolouian, Mohammadreza Ardalan* , Ali Taghizadieh, Mojtaba Varshochi, Soheil Teimouri, Tahere Vaezi, Hamed Valizadeh, Parviz Saleh, Saeid Safiri , Kenneth R. Chapman

Bioimpacts. 2020;10(4): 209-215. doi: 10.34172/bi.2020.27

PMCID: PMC7502909 PMID: 32983936 Scopus ID: 85092050012

Article

PDF

Full Text

XML

Cited By:

Based on a randomized clinical trial, bromhexine is proposed as a potential therapeutic option in COVID-19. A total of 78 patients with similar demographic and disease characteristics were treated with results showing a significant reduction in ICU admissions.

Submit Your Paper Instructions for Authors Aims and Scope Editorial Board Editorial Policies Publication Ethics Policies Editorial Board Policy Abstracting and Indexing Archive

As a peer-reviewed international open-access journal, BioImpacts publishes articles on basic and translational aspects of pharmaceutical and biomedical sciences.
Acceptance rate: 24%
Publication fee: Free of charge

Indexing/Abstracting Info
PubMed; PubMed Central; Scopus; Science Citation Index Expanded, Google Scholar; SJR ; Essential Science Indicators; Publons; Embase; EBSCOhost; CAS: DOAJ: SHERPA/RoMEO; Ulrich
Member of COPE
Follower of ICMJE
Permission: Creative Commons